PMID- 21252404
OWN - NLM
STAT- MEDLINE
DCOM- 20110629
LR  - 20180607
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 189
DP  - 2010 Dec
TI  - HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.
PG  - 16-20
AB  - A hypersensitivity reaction to abacavir develops in approximately 2-8% of HIV 
      patients receiving this drug and is strongly associated with presence of the 
      human leukocyte antigen (HLA)-B*5701. Screening for HLA-B*5701 reduces the risk 
      of developing an abacavir hypersensitivity reaction. The carriage rate of 
      HLA-B*5701 has not been studied in Georgia before 2009. Objective of the study 
      was to determine HLA-B*5701 prevalence in HIV-infected patients in Georgia. One 
      hundred and sixty HIV positive patients attending Georgian Infectious Diseases, 
      AIDS and Clinical Immunology Research Center in 2009 were recruited for the 
      study. None of the patients had previously been treated with abacavir. Blood 
      samples were collected and screened for HLA-B*5701 prior to abacavir 
      prescription. Of 160 patients recruited 9 tested HLA B*5701 positive - 5.6% (95% 
      CI: 2.6-10.4%). Of these nine patients 7 were males (male prevalence: 6.5%, 95% 
      CI: 2.6-12.9 %) and 2 females (female prevalence: 4.8%, 95% CI: 0.6-16.2%). The 
      first prospective study of HLA-B*5701 prevalence in Georgia show similar results 
      to the results of other studies. Abacavir still remains one of the key drugs of 
      antiretroviral regimens in Georgia and other countries. Therefore, prospective 
      HLA-B*5701 screening should be implemented in all settings where abacavir is 
      widely used to guide selection of ART regimens and to reduce the risk of 
      potentially life threatening hypersensitivity reaction.
FAU - Dvali, N
AU  - Dvali N
AD  - Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, 
      Georgia.
FAU - Chkhartishvili, N
AU  - Chkhartishvili N
FAU - Sharvadze, L
AU  - Sharvadze L
FAU - Karchava, M
AU  - Karchava M
FAU - Tsertsvadze, T
AU  - Tsertsvadze T
LA  - eng
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*57:01 antigen)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*adverse effects/immunology
MH  - Dideoxynucleosides/*adverse effects/immunology
MH  - Drug Hypersensitivity/genetics/prevention & control
MH  - Female
MH  - Genetic Markers
MH  - Genetic Testing
MH  - Georgia (Republic)
MH  - HIV/pathogenicity
MH  - HIV Infections/drug therapy/genetics
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Reverse Transcriptase Inhibitors/*adverse effects/immunology
EDAT- 2011/01/22 06:00
MHDA- 2011/06/30 06:00
CRDT- 2011/01/22 06:00
PHST- 2011/01/22 06:00 [entrez]
PHST- 2011/01/22 06:00 [pubmed]
PHST- 2011/06/30 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2010 Dec;(189):16-20.